Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00406575Phase 2Terminated

Recombinant Human Relaxin for the Treatment of Decompensated CHF

Role: lead

NCT00259103Phase 2Completed

Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor

Role: lead

NCT00520806Phase 2Completed

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

Role: lead

NCT00333307Phase 1Suspended

Evaluation of the Safety of Relaxin in Preeclampsia

Role: lead

NCT00259116Phase 2Completed

A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure

Role: lead

All 5 trials loaded